EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA
Executive Summary
The European Medicines Evaluation Agency approved four biological products in 1999 that have not yet been licensed by FDA.
You may also be interested in...
Wyeth Prevenar Approval Expected By End of February
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Biologicals Approved In 1999
Product.......... Humate-P (S, V) Ingredient....... Antihemophilic factor/von Willebrand factor complex (human) Sponsor.......... Centeon Pharma GmbH Indication....... New indication for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate Date Approved.... 4/1/1999 Application No... 96-1099 Footnote......... Standard review; Orphan drug
Novo's NovoRapid Has 10-20 Min. Onset Of Action - EU Labeling
Novo Nordisk's diabetes mellitus treatment insulin aspart has an onset of action time of 10 to 20 minutes, according to European draft labeling for the human insulin analogue.